Bacteroides fragilis (BF839) Combined with Laetiporus sulphureus in Improving Appetite in Malignant Tumor Patients

Clinical Efficacy and Mechanism Study of Bacteroides fragilis (BF839) Combined with Laetiporus sulphureus in Improving Appetite and Gastrointestinal Function in Malignant Tumor Patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600116292

Enrollment

Unknown

Registered

2026-01-07

Start date

2026-01-20

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumor patients with poor appetite/anorexia

Interventions

Control group:Conventional tumor diet education

Test group:Conventional tumor diet education+taking Bacteroides fragilis (BF839) Combined with Laetiporus sulphureus

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosed with malignant tumor; 2.The treatment plan remains unchanged for one month before and after participation; 3. Cancer Appetite Symptom Questionnaire (CASQ) score: >15 points, =4 points; 4. Expected survival duration > 3 months; 5. No severe dysfunction of heart, liver, kidney, or lung;

Exclusion criteria

Exclusion criteria: 1. Currently using megestrol acetate and hormones; 2.Patients with obvious gastrointestinal dysfunction, including gastrointestinal bleeding and obstructive intestinal obstruction; 3.Currently taking antibiotics; 4.Taking probiotics or undergoing fecal microbiota transplantation within one month before enrollment;

Design outcomes

Primary

Measure	Time frame
Gastrointestinal Symptom Rating Scale (GSRS);Cancer marker;Food intake scale score;albumin;Cancer Patient Appetite Symptoms Questionnaire (CASQ);EORTC QLQ-C30;Appetite Scale;	—

Secondary

Measure	Time frame
Analysis of gut microbiota;	—

Countries

China

Contacts

Public ContactZeng Ting

The Second Affiliated Hospital of Guangzhou Medical University

328598897@qq.com+86 20 34152396

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026